Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

Michael Slade; Thomas G. Martin; Nitya Nathwani; Mark A. Fiala; Michael P. Rettig; Feng Gao; Abhinav Deol; Francis K. Buadi; Jonathan L. Kaufman; Craig C. Hofmeister; Tara K. Gregory; Jesus Berdeja; Ajai Chari; Ashley Rosko; Ravi Vij

doi:10.1038/s41375-022-01691-1

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

Michael Slade, Thomas G. Martin, Nitya Nathwani, Mark A. Fiala, Michael P. Rettig, Feng Gao, Abhinav Deol, Francis K. Buadi, Jonathan L. Kaufman, Craig C. Hofmeister, Tara K. Gregory, Jesus Berdeja, Ajai Chari, Ashley Rosko, Ravi Vij

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Original language	English
Pages (from-to)	2917-2921
Number of pages	5
Journal	Leukemia
Volume	36
Issue number	12
DOIs	https://doi.org/10.1038/s41375-022-01691-1
State	Published - Dec 2022

Access to Document

10.1038/s41375-022-01691-1

Cite this

Slade, M., Martin, T. G., Nathwani, N., Fiala, M. A., Rettig, M. P., Gao, F., Deol, A., Buadi, F. K., Kaufman, J. L., Hofmeister, C. C., Gregory, T. K., Berdeja, J., Chari, A., Rosko, A., & Vij, R. (2022). Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia, 36(12), 2917-2921. https://doi.org/10.1038/s41375-022-01691-1

@article{cb229c45e8f34332988aae93f56c0f35,

title = "Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma",

author = "Michael Slade and Martin, {Thomas G.} and Nitya Nathwani and Fiala, {Mark A.} and Rettig, {Michael P.} and Feng Gao and Abhinav Deol and Buadi, {Francis K.} and Kaufman, {Jonathan L.} and Hofmeister, {Craig C.} and Gregory, {Tara K.} and Jesus Berdeja and Ajai Chari and Ashley Rosko and Ravi Vij",

note = "Funding Information: The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA91842. MS was supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR002344. MPR was supported by an NCI Research Specialist Award (R50CA211466). This study was also supported (in part) by research funding from Takeda, who provided ixazomib and material support for the trial, and Adaptive Biotechnologies, who performed clonoSEQ analysis at no charge. Funding Information: The trial (MMRC-066) was conducted at 10 Multiple Myeloma Research Consortium (MMRC) member institutions across the United States and included transplant-eligible patients age 18–70 with symptomatic NDMM who had received ≥2 cycles of induction. Full eligibility criteria are included in the . The study was conducted per the Declaration of Helsinki and registered at www.clinicaltrials.gov (#NCT02253316). The data cutoff for this analysis was March 31st, 2021. Takeda provided financial support for the trial and supplied ixazomib at no charge. Adaptive Biotechnologies provided MRD analysis at no charge. ",

year = "2022",

month = dec,

doi = "10.1038/s41375-022-01691-1",

language = "English",

volume = "36",

pages = "2917--2921",

journal = "Leukemia",

issn = "0887-6924",

number = "12",

}

Slade, M, Martin, TG, Nathwani, N, Fiala, MA , Rettig, MP , Gao, F, Deol, A, Buadi, FK, Kaufman, JL, Hofmeister, CC, Gregory, TK, Berdeja, J, Chari, A, Rosko, A & Vij, R 2022, 'Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma', Leukemia, vol. 36, no. 12, pp. 2917-2921. https://doi.org/10.1038/s41375-022-01691-1

TY - JOUR

T1 - Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

AU - Slade, Michael

AU - Martin, Thomas G.

AU - Nathwani, Nitya

AU - Fiala, Mark A.

AU - Rettig, Michael P.

AU - Gao, Feng

AU - Deol, Abhinav

AU - Buadi, Francis K.

AU - Kaufman, Jonathan L.

AU - Hofmeister, Craig C.

AU - Gregory, Tara K.

AU - Berdeja, Jesus

AU - Chari, Ajai

AU - Rosko, Ashley

AU - Vij, Ravi

N1 - Funding Information: The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA91842. MS was supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR002344. MPR was supported by an NCI Research Specialist Award (R50CA211466). This study was also supported (in part) by research funding from Takeda, who provided ixazomib and material support for the trial, and Adaptive Biotechnologies, who performed clonoSEQ analysis at no charge. Funding Information: The trial (MMRC-066) was conducted at 10 Multiple Myeloma Research Consortium (MMRC) member institutions across the United States and included transplant-eligible patients age 18–70 with symptomatic NDMM who had received ≥2 cycles of induction. Full eligibility criteria are included in the . The study was conducted per the Declaration of Helsinki and registered at www.clinicaltrials.gov (#NCT02253316). The data cutoff for this analysis was March 31st, 2021. Takeda provided financial support for the trial and supplied ixazomib at no charge. Adaptive Biotechnologies provided MRD analysis at no charge.

PY - 2022/12

Y1 - 2022/12

UR - http://www.scopus.com/inward/record.url?scp=85138152549&partnerID=8YFLogxK

U2 - 10.1038/s41375-022-01691-1

DO - 10.1038/s41375-022-01691-1

M3 - Article

C2 - 36114265

AN - SCOPUS:85138152549

SN - 0887-6924

VL - 36

SP - 2917

EP - 2921

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

Access to Document

Other files and links

Cite this